UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years

Diabetic Medicine

Volumn 15, Issue 4, 1998, Pages 297-303

  Matthews, D R ^a   Cull, C A ^b   Stratton, I M ^b   Holman, R R ^b   Turner, R C ^b  

^a RADCLIFFE INFIRMARY   (United Kingdom)

^b NONE

Author keywords

Chlorpropramide; Glibenclamide; Non insulin dependent diabetes; Sulphonylurea therapy

Indexed keywords

CHLORPROPAMIDE; GLIBENCLAMIDE; INSULIN; INSULIN ZINC SUSPENSION; METFORMIN; SULFONYLUREA DERIVATIVE;

ADULT; AGED; ARTICLE; BODY MASS; CLINICAL TRIAL; CONTROLLED STUDY; DIET THERAPY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RELEASE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ONSET AGE; PANCREAS ISLET BETA CELL; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE;

ADULT; BLOOD GLUCOSE; BODY MASS INDEX; CHLORPROPAMIDE; DIABETES MELLITUS, TYPE 2; FASTING; FEMALE; GLYBURIDE; GREAT BRITAIN; HUMANS; HYPOGLYCEMIC AGENTS; ISLETS OF LANGERHANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT FAILURE;

EID: 0031972156     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9136(199804)15:4<297::AID-DIA572>3.0.CO;2-W     Document Type: Article

References (19)

1. UK Prospective Diabetes Study. I. Effect of diet, sulphonylurea, insulin or biguanide therapy on fasting plasma glucose and body weight over one year. Diabetologia 1983; 24: 404-411.
2. Harrower ADB. Comparison of efficacy, secondary failure rate, and complications of sulfonylureas. J Diabetes Complications 1994; 8: 201-203.
3. Turner RC, Holman RR, Matthews DR. Sulphonylurea failure and inadequacy. In: Cameron D, Colagiuri S, Heding L, Kuhl D, Mortimer R, eds. Non-insulin Dependent Diabetes Mellitus. Amsterdam: Excerpta Medica, 1988: 52-56.
4. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
5. Eschwege E, Richard JL, Thibult N, Ducimetiere P, Warnet JM, Claude JR, et al. Coronary heart disease mortality in relation with diabetes, blood glucose and plasma insulin levels. The Paris Prospective Study, ten years later. Horm Metab Res Suppl 1985; 15: 41-46.
6. Jarrett RJ, Shipley MJ. Type 2 (non-insulin-dependent) diabetes mellitus and cardiovascular disease-putative association via common antecedents; further evidence from the Whitehall Study. Diabetologia 1988; 31: 737-740.
7. UKPDS Group. UK Prospective Diabetes Study 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. Br Med J 1995; 310: 83-88.
8. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
9. UKPDS Group. UK Prospective Diabetes Study VIII: Study design, progress and performance. Diabetologia 1991; 34: 877-890.
10. Keen H, Jarrett RJ, McCartney P. The ten-year follow-up of the Bedford survey (1962-1972): glucose tolerance and diabetes. Diabetologia 1982; 22: 73-78.
11. Jarrett RJ, Keen H, McCartney P. The Whitehall Study: ten year follow-up report on men with impaired glucose tolerance with reference to worsening to diabetes and predictors of death. Diabetic Med 1984; 1: 279-283.
12. UKPDS Group. UK Prospective Diabetes Study 16: Overview of six years' therapy of type 2 diabetes - a progressive disease. Diabetes 1995; 44: 1249-1258.
13. Westermark P, Wilander E. The influence of amyloid deposits on the islet volume in maturity onset diabetes mellitus. Diabetologia 1978; 15: 417-421.
14. Clark A, Wells CA, Buley ID, Cruickshank JK, Vanhegan RI, Matthews DR, et al. Islet amyloid, increased A-cells, reduced B-cells and exocrine fibrosis: quantitative changes in the pancreas in type 2 diabetes. Diabetes Res 1988; 9: 151-159.
15. Dimitriadis G, Cryer P, Gerich J. Prolonged hyperglycaemia during infusion of glucose and somatostatin impairs pancreatic A-and B-cell responses to decrements in plasma glucose in normal man: evidence for induction of altered sensitivity to glucose. Diabetologia 1985; 28: 63-69.
16. Zimmett PZ, Tuomi T, Mackay IR, Rowley MJ, Knowles W, Cohen M, et al. Latent autoimmune diabetes mellitus in adults (LADA): the role of antibodies to glutamic acid decarboxylase in diagnosis and prediction of insulin dependency. Diabetic Med 1994; 11: 299-303.
17. Groop LC, Bottazzo GF, Doniach D. Islet cell antibodies identify latent Type 1 diabetes in patients aged 35-75 years at diagnosis. Diabetes 1986; 35: 237-241.
18. UKPDS Group. UK Prospective Diabetes Study 25: Clinical value of ICA and GADA in predicting insulin requirement in patients with newly diagnosed NIDDM at different ages. Lancet 1997; 350: 1288-1293.
19. Clarke BF, Campbell IW. Long-term comparative trial of glibenclamide and chlorpropamide in diet-failed, maturity-onset diabetics. Lancet 1975; 1: 246-248.